Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis
Early-stage apoptotic cells possess immunomodulatory properties. Proper apoptotic cell clearance during homeostasis has been shown to limit subsequent immune responses. Based on these observations, early-stage apoptotic cell infusion has been used to prevent unwanted inflammatory responses in differ...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01191/full |
| _version_ | 1819056150752002048 |
|---|---|
| author | Philippe Saas Philippe Saas Francis Bonnefoy Eric Toussirot Eric Toussirot Eric Toussirot Sylvain Perruche |
| author_facet | Philippe Saas Philippe Saas Francis Bonnefoy Eric Toussirot Eric Toussirot Eric Toussirot Sylvain Perruche |
| author_sort | Philippe Saas |
| collection | DOAJ |
| description | Early-stage apoptotic cells possess immunomodulatory properties. Proper apoptotic cell clearance during homeostasis has been shown to limit subsequent immune responses. Based on these observations, early-stage apoptotic cell infusion has been used to prevent unwanted inflammatory responses in different experimental models of autoimmune diseases or transplantation. Moreover, this approach has been shown to be feasible without any toxicity in patients undergoing allogeneic hematopoietic cell transplantation to prevent graft-versus-host disease. However, whether early-stage apoptotic cell infusion can be used to treat ongoing inflammatory disorders has not been reported extensively. Recently, we have provided evidence that early-stage apoptotic cell infusion is able to control, at least transiently, ongoing collagen-induced arthritis. This beneficial therapeutic effect is associated with the modulation of antigen-presenting cell functions mainly of macrophages and plasmacytoid dendritic cells, as well as the induction of collagen-specific regulatory CD4+ T cells (Treg). Furthermore, the efficacy of this approach is not altered by the association with two standard treatments of rheumatoid arthritis (RA), methotrexate and tumor necrosis factor (TNF) inhibition. Here, in the light of these observations and recent data of the literature, we discuss the mechanisms of early-stage apoptotic cell infusion and how this therapeutic approach can be transposed to patients with RA. |
| first_indexed | 2024-12-21T13:18:51Z |
| format | Article |
| id | doaj.art-0a671b27008c4502a6e0adc4d8a48679 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-21T13:18:51Z |
| publishDate | 2017-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-0a671b27008c4502a6e0adc4d8a486792022-12-21T19:02:38ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-10-01810.3389/fimmu.2017.01191298070Harnessing Apoptotic Cell Clearance to Treat Autoimmune ArthritisPhilippe Saas0Philippe Saas1Francis Bonnefoy2Eric Toussirot3Eric Toussirot4Eric Toussirot5Sylvain Perruche6INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Université Bourgogne Franche-Comté, Besançon, FranceINSERM CIC-1431, University Hospital of Besançon, Clinical Investigation Center in Biotherapy, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, FranceINSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Université Bourgogne Franche-Comté, Besançon, FranceINSERM CIC-1431, University Hospital of Besançon, Clinical Investigation Center in Biotherapy, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, FranceDepartment of Rheumatology, University Hospital of Besançon, Besançon, FranceDepartment of Therapeutics, Université Bourgogne Franche-Comté, UPRES EA 4266, Pathogenic Agents and Inflammation, Besancon, FranceINSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Université Bourgogne Franche-Comté, Besançon, FranceEarly-stage apoptotic cells possess immunomodulatory properties. Proper apoptotic cell clearance during homeostasis has been shown to limit subsequent immune responses. Based on these observations, early-stage apoptotic cell infusion has been used to prevent unwanted inflammatory responses in different experimental models of autoimmune diseases or transplantation. Moreover, this approach has been shown to be feasible without any toxicity in patients undergoing allogeneic hematopoietic cell transplantation to prevent graft-versus-host disease. However, whether early-stage apoptotic cell infusion can be used to treat ongoing inflammatory disorders has not been reported extensively. Recently, we have provided evidence that early-stage apoptotic cell infusion is able to control, at least transiently, ongoing collagen-induced arthritis. This beneficial therapeutic effect is associated with the modulation of antigen-presenting cell functions mainly of macrophages and plasmacytoid dendritic cells, as well as the induction of collagen-specific regulatory CD4+ T cells (Treg). Furthermore, the efficacy of this approach is not altered by the association with two standard treatments of rheumatoid arthritis (RA), methotrexate and tumor necrosis factor (TNF) inhibition. Here, in the light of these observations and recent data of the literature, we discuss the mechanisms of early-stage apoptotic cell infusion and how this therapeutic approach can be transposed to patients with RA.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01191/fullapoptotic cellsrheumatoid arthritiscollagen-induced arthritismacrophagesregulatory T cellsefferocytosis |
| spellingShingle | Philippe Saas Philippe Saas Francis Bonnefoy Eric Toussirot Eric Toussirot Eric Toussirot Sylvain Perruche Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis Frontiers in Immunology apoptotic cells rheumatoid arthritis collagen-induced arthritis macrophages regulatory T cells efferocytosis |
| title | Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis |
| title_full | Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis |
| title_fullStr | Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis |
| title_full_unstemmed | Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis |
| title_short | Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis |
| title_sort | harnessing apoptotic cell clearance to treat autoimmune arthritis |
| topic | apoptotic cells rheumatoid arthritis collagen-induced arthritis macrophages regulatory T cells efferocytosis |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01191/full |
| work_keys_str_mv | AT philippesaas harnessingapoptoticcellclearancetotreatautoimmunearthritis AT philippesaas harnessingapoptoticcellclearancetotreatautoimmunearthritis AT francisbonnefoy harnessingapoptoticcellclearancetotreatautoimmunearthritis AT erictoussirot harnessingapoptoticcellclearancetotreatautoimmunearthritis AT erictoussirot harnessingapoptoticcellclearancetotreatautoimmunearthritis AT erictoussirot harnessingapoptoticcellclearancetotreatautoimmunearthritis AT sylvainperruche harnessingapoptoticcellclearancetotreatautoimmunearthritis |